Activation of the ERK1/2 pathway is a key downstream target of BCR signaling and is associated with increased CLL B cells survival, resistance to chemotherapy and upregulation of chemokine secretion [44]. The gene discussed is MAPK3; the disease is B-cell chronic lymphocytic leukemia.